Galectin Therapeutics, Inc. (GALT) to Present at American Association for the Study of Liver Disease

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, recently announced that it has been asked to present at the American Association for the Study of Liver Disease (AASLD) Annual Meeting on November 12, 2012, in Boston MA.

Galectin Therapeutics’ lead galectin inhibitor compound, GR-MD-02 — based on preclinical data — has demonstrated the ability to prevent and reverse the formation of fibrosis in animal models of non-alcoholic steatohepatitis (NASH), or fatty liver disease. Galectin has stated that its presentation at AASLD will extend understanding about the mechanism by which GR-MD-02 improves pathology in NASH, which represents an important unmet medical need.

Galectin Therapeutics recently hosted the International Conference on Galectins and Disease, held at the Harvard Club in Boston, MA, on September 17-19, 2012. Proceedings from the international meeting have been accepted for publication by the American Chemical Society. Entitled “Galectins and Disease: Implications for Targeted Therapeutics”, the book is expected to be published in early 2013 and is edited by Dr. Anatole A. Klyosov, Chief Scientist and Founder, and Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer.

Dr. Traber, President, CEO, and Chief Medical Officer of Galectin Therapeutics, noted, “Presentations by international experts in galectin biology and disease confirmed the critical importance of galectin proteins in organ fibrosis and cancer. We are pleased that our preclinical data and development programs in liver fibrosis and melanoma were well represented and received by the scientists at the meeting. It was broadly agreed by the participants that this decade will herald the realization of galectin-targeted therapeutics in multiple diseases.”

Dr. Traber continued, stressing the importance the data of this research represents, saying, “In addition to the importance in cancer, the critical role of galectin-3 protein in fibrosis of multiple organs was emphasized, including liver, lung, kidney and heart. In fact, one of the speakers indicated that fibrosis of these organs, the ultimate cause of organ failure, accounts for 45% of all mortality in the United States.”

Galectin became an industry leader in its use of unique carbohydrate technology to target galectin proteins, which are key mediators of biologic and pathologic function. Using this process, Galectin makes use of natural occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific weight. Using these newly formed carbohydrate compounds, which bind and inhibit galectin process, the company is developing therapies for indications where galectins have demonstrated role in the pathogenesis of a particular disease.

For more information on Galectin Therapeutics, visit www.galectintherapeutics.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html